Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Short Interest Update

Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) saw a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 7,300 shares, a decline of 33.6% from the February 13th total of 11,000 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average daily volume of 14,300 shares, the short-interest ratio is currently 0.5 days.

Institutional Trading of Lakeshore Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of LSB. Barclays PLC purchased a new stake in shares of Lakeshore Biopharma during the third quarter worth about $169,000. Orbimed Advisors LLC purchased a new stake in Lakeshore Biopharma during the 4th quarter valued at about $486,000. Hhlr Advisors LTD. purchased a new stake in Lakeshore Biopharma during the 3rd quarter valued at about $513,000. Finally, FMR LLC purchased a new stake in Lakeshore Biopharma during the 3rd quarter valued at about $803,000. Hedge funds and other institutional investors own 52.64% of the company’s stock.

Lakeshore Biopharma Trading Up 2.3 %

Shares of Lakeshore Biopharma stock traded up $0.05 during trading hours on Monday, reaching $2.05. The stock had a trading volume of 2,147 shares, compared to its average volume of 19,912. The stock’s 50 day moving average is $2.45 and its 200 day moving average is $3.38. Lakeshore Biopharma has a twelve month low of $1.81 and a twelve month high of $11.20. The company has a current ratio of 1.17, a quick ratio of 0.90 and a debt-to-equity ratio of 0.13.

About Lakeshore Biopharma

LakeShore Biopharma Co, Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions.